



Date: November 7, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Outcome of Board Meeting in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Board of Directors of the Company at its Meeting held on Tuesday, November 7, 2023, inter-alia considered and approved the Unaudited Financial Results for the Quarter and half year ended September 30, 2023.

The Financials Results will be published in newspapers as required under the Listing Regulations.

The Meeting of the Board of Directors of the Company commenced at 03:15 p.m. and concluded at 04:40 p.m.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com



(₹ In million)

Sr.No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Half Year ended	Half Year ended	Year ended
		30-09-2023	30-06-2023	30-09-2022	30-09-2023	30-09-2022	31-03-2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	1,400.95	1,320.21	1,121.72	2,721.16	2,135.28	4,609.38
II	Other Income	24.67	29.18	26.05	53.85	49.61	94.89
III	Total Income	1,425.62	1,349.38	1,147.77	2,775.01	2,184.89	4,704.27
2	Expenses						
	a) Cost of Materials Consumed	507.03	475.28	424.94	982.31	850.79	1,873.18
	b) Purchase of Stock in Trade	-	-	-	-	-	-
	c) Change in inventories of finished goods, work in progress & stock in trade.	109.36	(3.08)	43.98	106.28	(31.75)	(65.06)
	d. Employee benefit expenses	175.02	154.28	129.63	329.30	256.33	555.78
	e. Finance Cost	4.60	5.56	7.75	10.15	13.56	30.84
	f. Depreciation & amortisation expense	39.81	39.55	29.73	79.37	58.58	118.15
	g. Other expenditure	292.02	251.42	237.55	543.45	461.82	956.49
IV	Total Expenses	1,127.84	923.01	873.58	2,050.85	1,609.34	3,469.40
V	Profit/(loss) before Exceptional Items & Tax (III -IV)	297.78	426.38	274.19	724.16	575.55	1,234.87
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) before Tax (V-VI)	297.78	426.38	274.19	724.16	575.55	1,234.87
VIII	Tax Expense						
	a) Current Tax	85.38	99.63	104.66	185.01	150.53	306.81
	b) Deferred Tax	(26.44)	41.63	0.91	15.20	3.91	29.49
	c) Income Tax for Earlier Years	-	-	-	-	-	-
IX	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	238.84	285.11	168.62	523.95	421.11	898.57
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	Profit/(Loss) from discontinued operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	238.84	285.11	168.62	523.95	421.11	898.57
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	(1.84)	19.47	(0.38)	17.63	(10.24)	(16.80)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	0.46	(4.90)	0.10	(4.44)	2.58	4.23
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)	237.46	299.68	168.33	537.14	413.44	886.00
XVI	Earnings per equity Share (for continuing operation):						
	(1) Basic (In ₹)	2.97	3.54	2.10	6.51	5.23	11.16
	(2) Diluted (In ₹)	2.97	3.54	2.10	6.51	5.23	11.16
XVII	Earnings per equity Share (for discontinued operation):						
	(1) Basic (In ₹)	-	-	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-	-	-
XVIII	Earnings per equity Share (for discontinued & continuing operations):						
	(1) Basic (In ₹)	2.97	3.54	2.10	6.51	5.23	11.16
	(2) Diluted (In ₹)	2.97	3.54	2.10	6.51	5.23	11.16

Notes:-

- The Unaudited Standalone financial results of the Company for the quarter & half year ended September 30, 2023 have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as ammended.
- The above Unaudited standalone financial results of the Company for the quarter & half year ended September 30, 2023 have been reviewed by the Audit Committee on 07th November, 2023 and thereafter approved by the Board of Directors at their meeting held on 07th November, 2023.
- The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
- The figures of the previous periods have been regrouped wherever necessary to conform to the current period presentation.
- The standalone financial results include the results for the quarter ended 30 September 2023 being the balancing figure between the Unaudited figures in respect of the half year ended September 30, 2023 and the published unaudited year to date figures up to the first quarter of the current financial year which were subject to limited review by us.

PLACE :- MUMBAI
 DATE :- 07-11-2023



For and on behalf of The Board of directors of
 Supriya Lifescience Ltd.

Dr. Satish Waman Wagh
 Chairman & Managing Director
 DIN: 01456982



Supriya Lifescience Ltd

CIN No: L51900MH2008PLC180452

Standalone Balance Sheet as at September 30, 2023

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	Notes	September 30, 2023	March 31, 2023
ASSETS			
Non-current assets			
(i) Property, plant and equipment	3	2,514.81	2,551.17
(ii) Right to Use Asset	3	50.72	53.15
(iii) Capital Work in progress	5	1,164.58	676.28
(iv) Intangible Assets	4	12.66	11.06
(v) Financial Assets		-	-
-Investments	6	569.53	252.96
-Loans and Advances	7	-	-
(vi) Other Non- Current Assets	8	9.35	9.28
Total Non-current assets		4,321.66	3,553.90
Current assets			
(i) Inventories	9	988.25	1,157.70
(ii) Financial Assets		-	-
-Loans and Advances	7	5.56	5.49
-Trade receivables	10	848.35	846.64
-Cash and cash equivalents	11(a)	1,040.41	852.51
-Bank balances other than (iii) above	11(a)	117.67	723.31
-Other Financial Assets	11(b)	44.80	64.06
(iii) Other current assets	12	1,063.60	999.16
Total Current Assets		4,108.64	4,648.87
TOTAL ASSETS		8,430.30	8,202.77
EQUITY AND LIABILITIES			
EQUITY			
(i) Equity share capital	13	160.97	160.97
(ii) Other equity	14	7,370.76	6,833.62
Total Equity		7,531.73	6,994.58
LIABILITIES			
Non-current liabilities			
(i) Financial Liabilities			
-Borrowings	15	-	-
-Lease Liabilities	16	52.61	54.89
-Other financial liabilities	17	-	-
(ii) Provisions	18	38.16	58.75
(iii) Deferred tax Liabilities	20	151.95	136.75
Total Non-Current Liabilities		242.73	250.39
Current liabilities			
(i) Financial liabilities			
-Borrowings	15	1.01	166.25
-Lease Liabilities	16	4.09	3.54
-Trade payables	19	551.97	642.28
-Other financial liabilities	17	21.08	8.21
(ii) Provisions	18	8.37	8.37
(iii) Other current liabilities	21	69.33	129.16
Total Current Liabilities		655.85	957.80
TOTAL EQUITY AND LIABILITIES		8,430.30	8,202.77

For and on behalf of The Board of
directors of
Supriya Lifescience Ltd.



Dr. Satish Waman Wagh
Chairman & Managing Director
DIN: 01456982

PLACE :- MUMBAI
DATE :- 07/11/2023





Supriya Lifescience Ltd
CIN No: L51900MH2008PLC180452

Cash flow statement for the half year ended September 30, 2023
(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	For the half year ended September 30,2023	For the half year ended September 30,2022
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	724.16	575.55
<u>Adjustments for</u>		
Depreciation and Amortization	79.37	58.58
Interest Income	-46.77	-49.94
Finance Cost	10.15	13.56
Loss on Sale of fixed Assets	-	0.53
Non Cash Expenses	-2.95	3.10
Operating profit before working capital changes	763.96	601.37
Adjustments for movement in working capital		
Adjustments for (increase)/ decrease in operating assets		
Trade Receivables	-1.71	344.65
Inventories	169.46	-139.90
Other Current Assets	-64.44	-570.99
Financial Assets	19.25	15.55
Loans and Advances	-0.07	1.16
Other Non Current Assets	-0.07	-2.07
	122.41	-351.60
Adjustments for increase/ (decrease) in operating liabilities		
Trade payables	-90.31	48.54
Other Financial Liabilities	12.87	-4.15
Other Current liabilities	-17.10	-244.26
	-94.54	-199.87
(Income tax paid)/net of refund	-232.18	-150.53
Net Cash generated from Operating Activities	559.66	-100.64
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-530.49	-364.76
(Purchase)/ Sale of Investments	-316.57	-
Sale of fixed Assets	-	3.90
Interest Income	46.77	49.94
Net Cash generated/(outflow) from Investing Activities	-800.29	-310.91
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Shares	-	-
Increase/(Decrease) in Long term borrowings	-	-
Increase/(Decrease) in Short term borrowing	-165.24	91.37
Finance Cost	-10.15	-13.56
Dividend Paid	-	-48.29
Repayment of Lease liability	-1.72	-1.36
Net Cash generated from Financing Activities	-177.12	28.16
Net Increase/(Decrease) in Cash and Cash equivalents	-417.75	-383.39
Cash and Cash Equivalents at the end of previous period	1,575.82	2,279.08
Cash and Cash Equivalents as at the end of the reporting period	1,158.07	1,895.69

For and on behalf of The Board of directors of
Supriya Lifescience Ltd.




Dr. Satish Waman Wagh
Chairman & Managing Director
DIN: 01456982

PLACE :- MUMBAI
DATE :- 07/11/2023

KAKARIA AND ASSOCIATES LLP

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

YOUR REF.:

OUR REF.:

Independent Auditor's Limited Review Report on Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,

Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Supriya Lifescience Limited** ("the Company") for the quarter & half year ended September 30, 2023, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on November 07, 2023, has been compiled from the related IND AS Financial Statements which has been prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,

Mumbai - 400 053 Tel: 022 26744670. Email: mumbai@kakariaassociates.com,

Website: www.kakariaassociates.com



audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14th October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For,
Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601



CA. Ujwal K. Kakaria
Partner
Membership No. – 035416
Place: - Mumbai
Date: - 07th November, 2023
UDIN: - 23035416BGTHZT9985